Gilead stock rises after positive HIV treatment trial results

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline results from its Phase 3 ARTISTRY-1 trial for an investigational HIV treatment.

The biopharmaceutical company reported that its once-daily single-tablet regimen combining bictegravir and lenacapavir (BIC/LEN) met the primary success criterion for non-inferiority compared to multi-tablet antiretroviral therapy regimens in adults with HIV who are virologically suppressed.

The trial evaluated the percentage of participants with HIV-1 RNA levels ≥50 copies/mL at Week 48, as defined by the FDA snapshot algorithm. Gilead noted that the treatment was generally well tolerated, with no significant or new safety concerns identified.

This new combination could potentially offer a more convenient dosing option for people living with HIV who are currently on complex regimens. At baseline, participants in the ARTISTRY-1 trial were taking between 2 and 11 pills daily for HIV treatment, with approximately 40% taking their antiretrovirals more than once a day.

"Developing new effective, convenient regimens for those left behind by advances in medical research is necessary to close the unmet HIV treatment gap," said Chloe Orkin, Clinical Professor of Infection and Inequities at Queen Mary University of London.

Gilead plans to file the Phase 3 data from the ARTISTRY trials with regulatory authorities and submit detailed findings for presentation at a future scientific congress. The company is also conducting the Phase 3 ARTISTRY-2 trial, which is evaluating the safety and efficacy of switching from BIKTARVY to BIC/LEN in virologically suppressed people with HIV-1.

Bictegravir and lenacapavir in combination are investigational and not yet approved anywhere globally.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.